Home › Markets › Health Care › MRVI

Maravai LifeSciences Holdings Inc. (MRVI)

MRVI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$6.53
-7.51% on the day
Market cap
$1.7B
Small cap
Revenue · 2025
$185.7M
-28.3% on 2024
Net income · 2025
-$130.8M
-70.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerMRVI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001823239
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$185.7M
Net income-$130.8M
Operating income-$215.3M
Net margin-70.4%
Operating margin-115.9%
Revenue growth-28.3%
Cash$216.9M
Total assets$770.6M
P/E (computed)Net income was not positive
P/S (computed)9.1×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42021-09-13
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-08-07
Latest current report8-K2026-08-06
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 422 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-11.2%
1 month-4.1%
3 months-7.0%
Year to date+102.9%
1 year+99.8%
From 52-week high-26.7%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SEPNSepterna Inc.$36.41-3.05%$1.7B
BHVNBiohaven Ltd. Common Shares$11.42-3.30%$1.7B
NUVBNuvation Bio Inc.$4.72-3.67%$1.7B
BRVEBraveheart Bio Inc.$19.33-5.06%$1.7B
SRPTSarepta Therapeutics Inc. Common Stock (DE)$16.51-5.33%$1.7B
XNCRXencor Inc.$23.52-6.07%$1.7B
TRVITrevi Therapeutics Inc.$12.29-4.95%$1.8B
ZBIOZenas BioPharma Inc.$25.16-4.70%$1.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier